{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:26:33Z","timestamp":1793183193582,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012739","name":"Zogenix","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016372","name":"Desitin Arzneimittel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016372","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.yebeh.2022.108666","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T02:28:52Z","timestamp":1648175332000},"page":"108666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Trends in antiseizure medication prescription patterns among all adults, women, and older adults with epilepsy: A German longitudinal analysis from 2008 to 2020"],"prefix":"10.1016","volume":"130","author":[{"given":"Maja","family":"Hochbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Kienitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Habermehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Langenbruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stjepana","family":"Kovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Knake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"von Podewils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"von Brauchitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Hamacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Strzelczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent M.","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2022.108666_b0005","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/14656566.2020.1829594","article-title":"Pharmacological treatment of focal epilepsy in adults: an evidence based approach","volume":"22","author":"Mula","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.yebeh.2022.108666_b0010","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2147\/NDT.S256699","article-title":"Clinical management of drug resistant epilepsy: a review on current strategies","volume":"17","author":"Guery","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.yebeh.2022.108666_b0015","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211037430","article-title":"Efficacy and tolerability of antiseizure drugs","volume":"14","author":"Hakami","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.yebeh.2022.108666_b0020","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/epi.17137","article-title":"Relative importance of clinical outcomes and safety risks of antiseizure medication monotherapy for patients and physicians: Discrete choice experiment eliciting preferences in real-world study \u201cVOTE\u201d","volume":"63","author":"Rosenow","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108666_b0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.yebeh.2017.06.041","article-title":"Personalized translational epilepsy research - Novel approaches and future perspectives: Part I: Clinical and network analysis approaches","volume":"76","author":"Rosenow","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108666_b0030","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.yebeh.2010.11.004","article-title":"Offering patients choices: a pilot study of interactions in the seizure clinic","volume":"20","author":"Toerien","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108666_b0035","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/CPJ.0000000000000442","article-title":"Neurologist-patient communication about epilepsy in the United States, Spain, and Germany","volume":"8","author":"Stern","year":"2018","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.yebeh.2022.108666_b0040","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.yebeh.2015.01.033","article-title":"Shared decision-making in epilepsy management","volume":"47","author":"Pickrell","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108666_b0045","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00415-020-09809-0","article-title":"Expert opinion: use of valproate in girls and women of childbearing potential with epilepsy: recommendations and alternatives based on a review of the literature and clinical experience-a European perspective","volume":"268","author":"Toledo","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2022.108666_b0050","unstructured":"European Medicines Agency. New measures to avoid valproate exposure in pregnancy endorsed. In: Member State representatives agree new restrictions and pregnancy prevention programme; 2018."},{"key":"10.1016\/j.yebeh.2022.108666_b0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14581\/jer.19003","article-title":"Epilepsy in the elderly: treatment and consideration of comorbid diseases","volume":"9","author":"Lee","year":"2019","journal-title":"J Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108666_b0060","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.4103\/0972-2327.128645","article-title":"Epilepsy in the elderly: special considerations and challenges","volume":"17","author":"Acharya","year":"2014","journal-title":"Ann Indian Acad Neurol"},{"key":"10.1016\/j.yebeh.2022.108666_b0065","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.yebeh.2016.07.037","article-title":"Neurologist adherence to clinical practice guidelines and costs in patients with newly diagnosed and chronic epilepsy in Germany","volume":"64","author":"Strzelczyk","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108666_b0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.seizure.2016.07.001","article-title":"Guideline conform initial monotherapy increases in patients with focal epilepsy: a population-based study on German health insurance data","volume":"41","author":"Ertl","year":"2016","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108666_b0075","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.yebeh.2012.01.021","article-title":"Evaluation of health-care utilization among adult patients with epilepsy in Germany","volume":"23","author":"Strzelczyk","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108666_b0080","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.yebeh.2018.03.025","article-title":"Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 - a ten-year overview","volume":"83","author":"Willems","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108666_b0085","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40263-018-0544-2","article-title":"Use of emergency medication in adult patients with epilepsy: a multicentre cohort study from Germany","volume":"32","author":"Kadel","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2022.108666_b0090","doi-asserted-by":"crossref","DOI":"10.1111\/epi.17174","article-title":"Multicenter, cross-sectional study of the costs of illness and cost-driving factors in adult patients with epilepsy","author":"Willems","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108666_b0095","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/epi.13584","article-title":"Costs and cost-driving factors for acute treatment of adults with status epilepticus: a multicenter cohort study from Germany","volume":"57","author":"Kortland","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108666_b0100","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s10049-008-1057-1","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting of observational studies","volume":"11","author":"von Elm","year":"2008","journal-title":"Notfall Rettungsmedizin"},{"key":"10.1016\/j.yebeh.2022.108666_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.yebeh.2022.108666_b0110","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40258-019-00487-2","article-title":"General trends in prices and prescription patterns of anticonvulsants in Germany between 2000 and 2017: analysis of national and cohort-based data","volume":"17","author":"Willems","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.yebeh.2022.108666_b0115","unstructured":"World Health Organisation. Data portal - Maternal, newborn, child and adolescent health and aging. In: Health Indicators."},{"key":"10.1016\/j.yebeh.2022.108666_b0120","doi-asserted-by":"crossref","unstructured":"Singh S, Bajorek B. Defining 'elderly' in clinical practice guidelines for pharmacotherapy. Pharm Pract (Granada) 2014;12: 489.","DOI":"10.4321\/S1886-36552014000400007"},{"key":"10.1016\/j.yebeh.2022.108666_b0125","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","article-title":"Controlling the false discovery rate in behavior genetics research","volume":"125","author":"Benjamini","year":"2001","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.yebeh.2022.108666_b0130","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Royal Statis Soc"},{"key":"10.1016\/j.yebeh.2022.108666_b0135","doi-asserted-by":"crossref","first-page":"106503","DOI":"10.1016\/j.eplepsyres.2020.106503","article-title":"Prescription patterns of antiepileptic drugs for adult patients with newly diagnosed focal epilepsy from 2006 to 2017 in Japan","volume":"169","author":"Chen","year":"2021","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108666_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.649589","article-title":"Anti-seizure medication prescription in adult outpatients with epilepsy in China, 2013\u20132018","volume":"12","author":"Yu","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2022.108666_b0145","doi-asserted-by":"crossref","first-page":"108450","DOI":"10.1016\/j.yebeh.2021.108450","article-title":"Prescription patterns and dosages of antiepileptic drugs in prevalent patients with epilepsy in Taiwan: a nationwide retrospective cross-sectional study","volume":"126","author":"Liang","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108666_b0150","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030746","article-title":"First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study","volume":"9","author":"Menzler","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.yebeh.2022.108666_b0155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/epi.12432","article-title":"Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double-blind, randomized, placebo-controlled trial","volume":"55","author":"Ryvlin","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108666_b0160","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/epi.14476","article-title":"Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus","volume":"59","author":"Strzelczyk","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108666_b0165","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1111\/epi.17087","article-title":"Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: a longitudinal multicenter study with up to 5 years of follow-up","volume":"62","author":"Strzelczyk","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108666_b0170","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.seizure.2019.04.021","article-title":"Effect of brivaracetam on the anger levels of epilepsy patients. A prospective open-labelled controlled study","volume":"69","author":"Toledo","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108666_b0175","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ane.13059","article-title":"BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice","volume":"139","author":"Villanueva","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108666_b0180","first-page":"150","article-title":"Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from two randomized, double-blind, placebo-controlled trials","volume":"51","author":"Werhahn","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108666_b0185","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eplepsyres.2016.08.018","article-title":"Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: a pooled analysis from three phase III studies","volume":"127","author":"Brodie","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108666_b0190","first-page":"390","article-title":"Safety and tolerability of adjunctive brivaracetam administered as oral solution in pediatric patients aged \u22651 month to 16 years with epilepsy","volume":"14","author":"Liu","year":"2014","journal-title":"Epilepsy Currents"},{"key":"10.1016\/j.yebeh.2022.108666_b0195","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/epi.13768","article-title":"Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany","volume":"58","author":"Steinig","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108666_b0200","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fneur.2018.00569","article-title":"Efficacy, retention, and tolerability of brivaracetam in patients with epileptic encephalopathies: a multicenter cohort study from Germany","volume":"9","author":"Willems","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2022.108666_b0205","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12884-018-1842-x","article-title":"Sodium valproate in pregnancy: what are the risks and should we use a shared decision-making approach?","volume":"18","author":"Macfarlane","year":"2018","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.yebeh.2022.108666_b0210","article-title":"Dangers of valproate in pregnancy","volume":"361","author":"Wieck","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.yebeh.2022.108666_b0215","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.4103\/jfmpc.jfmpc_185_19","article-title":"Carbamazepine-induced hyponatremia - a wakeup call","volume":"8","author":"Kaeley","year":"2019","journal-title":"J Family Med Prim Care"},{"key":"10.1016\/j.yebeh.2022.108666_b0220","doi-asserted-by":"crossref","first-page":"262","DOI":"10.5455\/medarh.2018.72.262-266","article-title":"Effect of long-term carbamazepine therapy on bone health","volume":"72","author":"Suljic","year":"2018","journal-title":"Med Arch"},{"key":"10.1016\/j.yebeh.2022.108666_b0225","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40263-020-00698-5","article-title":"Pharmacological management of the genetic generalised epilepsies in adolescents and adults","volume":"34","author":"Stephen","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2022.108666_b0230","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108666_b0235","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/epi.12493","article-title":"Efficacy of perampanel: a review of pooled data","volume":"55","author":"Steinhoff","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108666_b0240","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.eplepsyres.2014.03.015","article-title":"A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria","volume":"108","author":"Steinhoff","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108666_b0245","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108666_b0250","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1080\/14656566.2019.1637420","article-title":"Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus","volume":"20","author":"Willems","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.yebeh.2022.108666_b0255","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eplepsyres.2012.06.005","article-title":"Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: a meta-analysis of randomized placebo-controlled trials","volume":"103","author":"Gao","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108666_b0260","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2022.108666_b0265","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(21)00247-6","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2022.108666_b0270","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1080\/17512433.2016.1254041","article-title":"A pharmacological overview of lamotrigine for the treatment of epilepsy","volume":"9","author":"Yasam","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2022.108666_b0275","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40120-021-00252-5","article-title":"Pregnancy and the control of epileptic seizures: a review","volume":"10","author":"Eadie","year":"2021","journal-title":"Neurol Ther"},{"key":"10.1016\/j.yebeh.2022.108666_b0280","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2022.108666_b0285","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/epi4.12420","article-title":"Global survey of guidelines for the management of epilepsy in pregnancy: a report from the international league against epilepsy task force on women and pregnancy","volume":"5","author":"Tomson","year":"2020","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2022.108666_b0290","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/jamaneurol.2021.1583","article-title":"Two-year-old cognitive outcomes in children of pregnant women with epilepsy in the maternal outcomes and neurodevelopmental effects of antiepileptic drugs study","volume":"78","author":"Meador","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2022.108666_b0295","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s13760-020-01488-y","article-title":"Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update","volume":"121","author":"Boon","year":"2021","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.yebeh.2022.108666_b0300","doi-asserted-by":"crossref","DOI":"10.1111\/ane.13581","article-title":"Valproate Restrictions in Sweden and Norway: Online survey suggests implementation deficit","author":"Zelano","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108666_b0305","doi-asserted-by":"crossref","first-page":"108650","DOI":"10.1016\/j.yebeh.2022.108650","article-title":"Gender differences in concerns about planning to have children and child-rearing among patients with epilepsy: A prospective, multicenter study with 477 patients from Germany","volume":"129","author":"Mann","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108666_b0310","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eplepsyres.2018.03.023","article-title":"Antiepileptic drugs-induced hyponatremia: review and analysis of 560 hospitalized patients","volume":"143","author":"Intravooth","year":"2018","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108666_b0315","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1111\/epi.13593","article-title":"Antiepileptic drugs and hyponatremia in older adults: two population-based cohort studies","volume":"57","author":"Gandhi","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108666_b0320","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13760-019-01132-4","article-title":"Antiepileptic drug therapy in the elderly: a clinical pharmacological review","volume":"119","author":"Kaur","year":"2019","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.yebeh.2022.108666_b0325","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3389\/fneur.2019.01171","article-title":"Bone mineral density loss in people with epilepsy taking valproate as a monotherapy: a systematic review and meta-analysis","volume":"10","author":"Zhong","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2022.108666_b0330","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.seizure.2021.11.018","article-title":"Predicting the occurrence of thrombocytopenia from free valproate levels: a prospective study","volume":"94","author":"Nasreddine","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108666_b0335","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1528-1157.1981.tb04094.x","article-title":"Sodium valproate, platelet dysfunction, and bleeding","volume":"22","author":"Loiseau","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108666_b0340","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1080\/14656566.2019.1618272","article-title":"New anti-seizure medication for elderly epileptic patients","volume":"20","author":"Watkins","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.yebeh.2022.108666_b0345","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40266-021-00865-3","article-title":"Adjunctive perampanel in older patients with epilepsy: a multicenter study of clinical practice","volume":"38","author":"Lattanzi","year":"2021","journal-title":"Drugs Aging"},{"key":"10.1016\/j.yebeh.2022.108666_b0350","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.yebeh.2019.02.022","article-title":"Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: a retrospective study","volume":"94","author":"Del Bianco","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108666_b0355","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/epi.16068","article-title":"The medical treatment of epilepsy in the elderly: a systematic review and meta-analysis","volume":"60","author":"Lezaic","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108666_b0360","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1111\/epi.16366","article-title":"Antiepileptic drug monotherapy for epilepsy in the elderly: a systematic review and network meta-analysis","volume":"60","author":"Lattanzi","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108666_b0365","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1586\/ern.10.3","article-title":"Levetiracetam: a comprehensive review","volume":"10","author":"Crepeau","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.yebeh.2022.108666_b0370","unstructured":"Elger C, Berkenfeld R. S1-Leitlinie Erster epileptischer Anfall und Epilepsien im Erwachsenenalter. In: Deutsche Gesellschaft f\u00fcr Neurologie: Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie; 2017, access date 08.08.2018."},{"key":"10.1016\/j.yebeh.2022.108666_b0375","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ane.13389","article-title":"Levetiracetam as first-line monotherapy for Idiopathic Generalized Epilepsy in women","volume":"143","author":"Ballv\u00e9","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108666_b0380","doi-asserted-by":"crossref","first-page":"106214","DOI":"10.1016\/j.eplepsyres.2019.106214","article-title":"Levetiracetam in genetic generalized epilepsy: a prospective unblinded active-controlled trial","volume":"157","author":"Tabrizi","year":"2019","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108666_b0385","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","article-title":"Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures","volume":"70","author":"Noachtar","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108666_b0390","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4997\/jrcpe.2020.409","article-title":"Retrospective studies - utility and caveats","volume":"50","author":"Talari","year":"2020","journal-title":"J R Coll Physicians Edinb"},{"key":"10.1016\/j.yebeh.2022.108666_b0395","doi-asserted-by":"crossref","first-page":"107483","DOI":"10.1016\/j.yebeh.2020.107483","article-title":"SARS-CoV-2-related rapid reorganization of an epilepsy outpatient clinic from personal appointments to telemedicine services: a German single-center experience","volume":"112","author":"Willems","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108666_b0400","doi-asserted-by":"crossref","first-page":"107833","DOI":"10.1016\/j.yebeh.2021.107833","article-title":"The impact of the coronavirus disease (COVID-19) pandemic on outpatient epilepsy care: an analysis of physician practices in Germany","volume":"117","author":"Mueller","year":"2021","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022001159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022001159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:47:25Z","timestamp":1761504445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505022001159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":80,"alternative-id":["S1525505022001159"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108666","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in antiseizure medication prescription patterns among all adults, women, and older adults with epilepsy: A German longitudinal analysis from 2008 to 2020","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108666","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108666"}}